Jan Stenvang

Jan Stenvang

Associate Professor

ORCID: 0000-0001-5647-4828

Publication year:
All
1 - 4 out of 4Page size: 500
Sort by: Title
  1. Published

    A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer

    Rasmussen, L. M., Zaveri, N. T., Stenvang, Jan, Peters, R. H. & Lykkesfeldt, A. E., 2007, In: Breast Cancer Research and Treatment. 106, 2, p. 191-203 12 p.

    Research output: Contribution to journal › Journal article › peer-review

  2. Published

    Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death

    Yde, C. W., Gyrd-Hansen, Mads, Lykkesfeldt, A. E., Issinger, O. & Stenvang, Jan, Jun 2007, In: Molecular Cancer Therapeutics. 6, 6, p. 1869-1876 8 p.

    Research output: Contribution to journal › Journal article › peer-review

  3. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT

    Yde, C. W., Frogne, T., Lykkesfeldt, A. E., Fichtner, I., Issinger, O. G. & Stenvang, Jan, 2007, In: Cancer Letters. 256, 2, p. 229-237 8 p.

    Research output: Contribution to journal › Journal article › peer-review

  4. Published

    Protein kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells

    Frankel, Lisa, Lykkesfeldt, A. E., Hansen, J. B. H. & Stenvang, Jan, 2007, In: Breast Cancer Research and Treatment. 104, 2, p. 165-179 14 p.

    Research output: Contribution to journal › Journal article › peer-review

ID: 12922